CliffBio
biologic

Benlysta

belimumab

Loss of exclusivityJuly 2029projected — 12-year biologic exclusivity estimate
CompanyGlaxoSmithKline →View the full company profile on CliffBio

Drug detail

Brand nameBenlysta
Active ingredientbelimumab
Strength200MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJuly 2017
Marketing statusRx

More from GlaxoSmithKline

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Benlysta patent cliff — loss of exclusivity July 2029 | CliffBio